The stock has a 36-month beta value of -1.05. Opinions on the stock are mixed, with 3 analysts rating it as a “buy,” 1 as “overweight,” 0 as “hold,” and 0 as “sell.”
The public float for CADL is 32.47M, and at present, short sellers hold a 10.28% of that float. On March 14, 2025, the average trading volume of CADL was 1.79M shares.
CADL) stock’s latest price update
Candel Therapeutics Inc (NASDAQ: CADL) has experienced a rise in its stock price by 8.31 compared to its previous closing price of 7.94. However, the company has seen a gain of 4.12% in its stock price over the last five trading days. proactiveinvestors.com reported 2025-03-13 that Candel Therapeutics Inc (NASDAQ:CADL) said on Thursday it is preparing to submit a Biologics License Application (BLA) for its lead candidate, CAN-2409, in prostate cancer, as the company pushes forward with late-stage development across multiple cancer indications. CEO Paul Peter Tak said the company enters 2025 “well-resourced with a clear direction,” focusing on regulatory readiness for CAN-2409’s potential approval.
CADL’s Market Performance
Candel Therapeutics Inc (CADL) has experienced a 4.12% rise in stock performance for the past week, with a 0.58% rise in the past month, and a 86.55% rise in the past quarter. The volatility ratio for the week is 7.48%, and the volatility levels for the past 30 days are at 11.22% for CADL. The simple moving average for the last 20 days is -3.99% for CADL’s stock, with a simple moving average of 27.78% for the last 200 days.
Analysts’ Opinion of CADL
Many brokerage firms have already submitted their reports for CADL stocks, with Citigroup repeating the rating for CADL by listing it as a “Buy.” The predicted price for CADL in the upcoming period, according to Citigroup is $25 based on the research report published on February 20, 2025 of the current year 2025.
Canaccord Genuity, on the other hand, stated in their research note that they expect to see CADL reach a price target of $20. The rating they have provided for CADL stocks is “Buy” according to the report published on February 19th, 2025.
BofA Securities gave a rating of “Buy” to CADL, setting the target price at $15 in the report published on February 07th of the current year.
CADL Trading at 4.12% from the 50-Day Moving Average
After a stumble in the market that brought CADL to its low price for the period of the last 52 weeks, the company was unable to rebound, for now settling with -41.10% of loss for the given period.
Volatility was left at 11.22%, however, over the last 30 days, the volatility rate increased by 7.48%, as shares sank -4.08% for the moving average over the last 20 days. Over the last 50 days, in opposition, the stock is trading +6.42% upper at present.
During the last 5 trading sessions, CADL rose by +2.42%, which changed the moving average for the period of 200-days by +8.46% in comparison to the 20-day moving average, which settled at $8.95. In addition, Candel Therapeutics Inc saw -0.92% in overturn over a single year, with a tendency to cut further losses.
Insider Trading
Reports are indicating that there were more than several insider trading activities at CADL starting from Barone Francesca, who sale 13,534 shares at the price of $7.22 back on Jan 15 ’25. After this action, Barone Francesca now owns 110,673 shares of Candel Therapeutics Inc, valued at $97,783 using the latest closing price.
Tyagarajan Seshu, the Chief Technology Officer of Candel Therapeutics Inc, sale 14,322 shares at $7.22 during a trade that took place back on Jan 15 ’25, which means that Tyagarajan Seshu is holding 96,790 shares at $103,476 based on the most recent closing price.
Stock Fundamentals for CADL
Current profitability levels for the company are sitting at:
- -20.02 for the present operating margin
- 0.54 for the gross margin
The net margin for Candel Therapeutics Inc stands at -29.39. The total capital return value is set at -5.69. Equity return is now at value -1344.47, with -145.85 for asset returns.
Based on Candel Therapeutics Inc (CADL), the company’s capital structure generated 20.92 points at debt to capital in total, while cash flow to debt ratio is standing at -1.79. The debt to equity ratio resting at -1.05. The interest coverage ratio of the stock is -14.98.
Currently, EBITDA for the company is -37.43 million with net debt to EBITDA at 0.01. When we switch over and look at the enterprise to sales, we see a ratio of 215.06. The liquidity ratio also appears to be rather interesting for investors as it stands at 1.18.
Conclusion
To sum up, Candel Therapeutics Inc (CADL) has seen a better performance recently. Analysts have differing views on the stock, with some seeing it as a “buy” and others as a “hold”. It’s important to note that the stock is currently trading at a significant distance from its 50-day moving average and its 52-week high.
